Only 5% of patients with a significant family history of breast cancer have an identifiable genetic syndrome1
Included in the Myriad MyRisk Hereditary Cancer test, RiskScore delivers a personalized 5-year and remaining lifetime risk for breast cancer.
RiskScore is the only breast cancer risk assessment test that incorporates the patient’s own clinical risk factors, family history, and unique genetic, ancestry-informed breast cancer risk markers.
For women tested in a preventive setting1, more than half will have a cancer risk high enough to warrant a medical management plan above what is recommended for the general population. A fraction are due to a high-risk mutation, and the majority are due to the patient’s personalized risk assessment, including RiskScore.
Included with both positive and negative results, the Myriad MyRisk Management Tool details relevant societal guidelines, personalized to your patient, based on their RiskScore and family history risk assessment. The easy-to-read format to provides you and your patient clarity and confidence as you form a plan together.
In order to address this need, Myriad continues to run one of the largest Genome Wide Association Studies (GWAS) for women of African ancestry in the world.
Given that genetic markers that are linked to breast cancer in one population may not convey the same risk across ancestries, Myriad performed extensive research to ensure that genetic markers are conveying the correct level of risk for patients.
By working with the Women’s Health Initiative (WHI), Myriad collaborated on a study of over 90,000 participants to determine the performance of the Tyrer-Cuzick risk model in patients of non-European ancestry.2
Barriers prevented polygenic risk scores for breast cancer from being available for women of all ancestries. In order to offer precision breast cancer risk assessment for women of all ancestries, Myriad took steps to address some of these challenges.
At Myriad Genetics, we believe that personalized genetic tests need to be accurate and accessible for people of all ancestries. Across our portfolio of products, we are committed to providing equity in care, investing in science that benefits patients of all ancestries, and the availability of precision genetic insights for all patients.
*Must also not have any blood relatives with a known high-risk breast cancer-related gene mutation. European or Ashkenazi Jewish patients with a CHEK2 mutation who meet other clinical eligibility criteria will receive a RiskScore.